2024 BioNJ C-Suite Summit

Welcome & Opening Remarks

• Debbie Hart, President & CEO, BioNJ
• Emer Leahy, MBA, Ph.D., President & CEO, PsychoGenics & Chair, BioNJ

Keynote: The Next Wave of Innovation in Life Sciences

Life sciences leaders are navigating a period of exciting innovation. Novel modalities and mechanisms of action have helped the industry address previously stubborn unmet needs. Over the past 10 years, R&D spend has increased, the pipeline has become more diverse and new asset approvals have accelerated. Looking ahead, policy reforms (e.g., IRA), a rapid proliferation in technological resources (e.g., AI, mRNA platforms) and a rise in cross-company collaborations suggest further change and opportunity. Join us in reflecting on what the future of life sciences innovation holds, and implications for large cap pharma companies, biotechs and life sciences investors. 

• Brandon Parry, MBA, Sr. Partner, McKinsey & Company

Panel: Harnessing Change to Deliver Impactful Innovation

Industry leaders will reflect on the state of innovation, expected industry shifts, latest thinking on development paradigms, portfolio shifts, the lasting implications of policy reforms, the impact of technological evolutions, talent priorities and more.

• Garrett Ingram, President & CEO, Cipla Therapeutics
• Will Lewis, MBA, J.D., Chair & CEO, Insmed
• Clive Meanwell, M.D., Chair & Partner, Population Health Partners
• Tarek Rabah, MBA, President & CEO, Otsuka Pharmaceuticals
• Scott White, MBA, Chief Operations Officer, NA Innovative Medicine, Johnson & Johnson
• Conversation Leader: Harriet Keane, Ph.D., Partner, McKinsey & Company

Fireside Chat: Policy Uncertainties in an Election Year

The past 18 months have borne witness to a rapidly evolving policy landscape (including but not limited to the IRA, IP, BIOSECURE) – with expected evolutions on the horizon compounded by a tumultuous election season. With the presidential election just a few weeks away, this session will explore potential health policy changes and implications for industry leaders.

• Hon. Jim Greenwood, Former Congressman & Former President & CEO, BIO
• Heather Meade, Principal, EY
• Conversation Leader: Lisa LeCointe-Cephas, J.D., Partner, Compliance & Investigations & Global Chair, Life Sciences Sector, DLA Piper

Networking Break

Panel: Market Access & Reimbursement
The market access landscape is intricate and constantly evolving, with payers persistently refining their business models and strategies. This panel will explore the essential groundwork for securing optimal reimbursement and payer coverage, which are crucial for ensuring Patient access to treatments and, ultimately, improving Patient care. The panel will also address key issues manufacturers face including changing legislation, consolidation, M&A, gross to net and commercial launch planning.

• Paul Hunter, Vice President, Market Access and Commercial Operations, Halozyme
• Christopher Jackson, J.D., Managing Member, The Law Office of Christopher S. Jackson
• Jake McDowell, Vice President, Head, Market Access, Pricing and Value, Partner Therapeutics
• Conversation Leader: Tom Evegan, Principal, Strategy & Management Consulting; National Consulting Leader Life Sciences, RSM

Panel: Topics in Talent: Attraction, Retention & Diversity
In the life sciences sector, talent development is crucial for fostering innovation and addressing complex challenges. Companies are focused on developing the next generation of talent by providing opportunities for education, training and mentorship. Additionally, there is a growing emphasis on upskilling and reskilling talent to leverage AI and other advanced technologies for greater efficiency and effectiveness. This discussion will explore key learnings from workplace evolutions and strategies companies can and must adopt such as equity.

• Britt Byers, Executive Vice President, Human Resources NA, Kyowa Kirin
• Vikki Conway, Sr. Vice President & Head, Human Resources, U.S., Teva Pharmaceuticals
• Kiran Dattani, MPH, MBA, Customer Success, Transformation, Strategy & Architecture, Google Cloud Healthcare & Life Sciences, Google
• Conversation Leader: Jan Campbell, Managing Partner Pharmaceuticals & Biotechnology, Korn Ferry

Fireside Chat: Research & Development in Mental Health
With Global Mental Health Day as the backdrop, this discussion features two pioneers in mental health research and development and will explore the challenges in developing therapeutics in the mental health space and how they can provide learnings in other areas.

• Husseini Manji, M.D., F.R.C.P.C., Professor, Oxford University; Co-Chair, UK Govt MH Mission; Former Global Head, Neuroscience, Janssen/Johnson & Johnson
• Conversation Leader: Emer Leahy, MBA, Ph.D., President & CEO, PsychoGenics & Chair, BioNJ

Networking Lunch

Panel: Continued Evolutions in Go-to-Market Models Including Patient Services
The continued evolution of the go-to-market (GTM) commercial model in life sciences has been characterized by a shift from push to pull strategies, the development of novel roles that rethink traditional functional boundaries in a compliant manner, and a simplification of the customer interface. This talk will explore how these approaches can enhance and improve Patient access to treatments given the complex journey that is the Patient experience. Getting it right can have a major impact on Patient outcomes, as Patient experience in healthcare continues to lag. personalized journeys.

• John Harlow, Chief Commercial Officer, Melinta Therapeutics
• Rohan Jain, General Manager, Commercial, Nusano
• Gina Murdoch, MBA, President & CEO, Multiple Sclerosis Association of America
• Conversation Leader: Haripriya Jain, MS, MBA, Executive Director, Global Value & Access Consulting,  Evidera, part of Thermo Fisher Scientific 

Panel: Evolving Capital Markets & Implications for Innovation
The life sciences industry market cap has more than tripled in a decade despite more recent challenges. This discussion will explore the latest funding environment (e.g., IPOs) and implications for industry.

• Aamir Mecklai, Managing Director, Healthcare Investment Banking, Bank of America
• Christopher Mortko,MBA, Ph.D., Vice President, Business Development & Licensing, Merck & Co.
• Monika Vnuk, M.D., Sr. Vice President, Global Partnering & Business Development, Sanofi
• Conversation Leader: Arda Ural, MBA, Ph.D., Americas Life Sciences Sector Leader, EY

Panel: The Digital & AI Era in the Biopharma Industry: How Can Companies Across Functions Transition from Hype Into Reality?
In the current environment, the biopharmaceutical industry is experiencing a transformative shift towards digitalization and AI adoption, promising improved efficiency, innovation and Patient outcomes. However, for companies to transition successfully from the hype surrounding these technologies into tangible benefits, they must integrate digital and AI solutions across functions, prioritize data-driven decision-making and foster a culture of innovation and adaptability.

• Sydney Klein, Chief Information Security Officer & Head of IT Core Services, Bristol Myers Squibb
• Hisham Hamadeh, Ph.D., Sr. Vice President & Global Head, Data Science & AI, Genmab
• Keith Koharski, MBA, Executive Director, Global Development IT, Regeneron
• Deiva Ramachandran, Ph.D., Partner, Generative AI-Automation Practice Leader, Healthcare, Life Sciences, State & Local Government, IBM
• Conversation Leader: Donna Conroy, Founder, CEO, SciMar ONE